Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Abstract

Monoclonal antibodies are believed to be magic bullets and hold great potential for lots of biological process. About 100 μg of mAb109 was expressed in 5 × 10 6 cells after 10 days’ immunization. 64 Cu-NOTA-mAb109 was synthesized with the specific activity of 0.74 MBq/μg and high in vitro stability. The binding affinity of 64 Cu-NOTA-mAb109 in A549 cells was determined to be 29.64 nM. 64 Cu-NOTA-mAb109 displayed prominent tumor accumulation from 2 h to 60 h p.i. (9.34 ± 0.67 %ID/g). NIRF imaging of Cy5.5-mAb109 showed high accumulation till 9 days p.i., while tumors nearly can not be observed in negative groups, which was confirmed by autoradiography. Immunohistological study confirmed that mAb109 had strong and specific capacity to bind lung adenocarcinoma (concentration to 58 nM). Our study demonstrated mAb109 was a new platform for the development of novel agent for lung adenocarcinoma noninvasive imaging. The resulted 64 Cu-NOTA-mAb109/Cy5.5-mAb109 show favorable imaging properties/specificity for A549 tumor and high sensitivity to human lung adenocarcinoma tissues.

Near-Infrared Fluorescence Tumor-Targeted Imaging in Lung Cancer: A Systematic Review

“…Since antibodies are already clinically available, they are relatively easy to implement as imaging agents in clinical settings. Three studies using antibodies conjugated to a NIR dye as a NIR fluorescent probe were included in this review [ 42 , 43 , 44 ].…”

“…Prdx1 is overexpressed in 50–80% of all lung cancers [ 85 , 88 ]. To create a fluorescent probe, mAb109 was conjugated to the fluorophore cyanine 5.5 (Cy5.5) [ 43 ]. The probe was tested in tumor-bearing mice.…”

Phenomic Imaging

“…For instance, mAb109 is a new platform for developing novel imaging agents for this type of cancer. Studies have shown that 64 Cu-NOTA-mAb109/Cy5.5-mAb109 exhibits high specificity and sensitivity for A549 tumors and human lung adenocarcinoma tissues (Zhu et al 2020 ). Furthermore, a CD146-targeting probe has been developed as a PET and NIRF imaging agent for hepatocellular carcinoma.…”

“…Immuno-PET has the potential to revolutionize personalized medicine by enabling better patient selection for antibody-based therapies and improving drug development. Despite being relatively expensive, it has been shown in several large multi-center randomized clinical trials to be a valuable primary patient screening method that can help avoid unnecessary procedures (Zhu et al 2020 ). By providing accurate diagnoses and assisting physicians in optimizing therapeutic decisions, immuno-PET can contribute to improving clinical practice and personalized medicine.…”

ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

“…[ 89 Zr]Zr-daratumumab uptake has been reported in the CD38-expressing lung cancer model ( 44 ). Other probes against RTK [HER2 ( 180 ) and Axl ( 36 )] and peroxiredoxin-I, a marker of oxidative stress ( 85 ), have also been assessed in NSCLC.…”